Biomedical Engineering Reference
In-Depth Information
immunosuppression by activated CD4 þ CD25 þ T cells.
J. Leukoc. Biol. 75, 785-791.
68. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM,
Nien YC, et al. (2007) Targeted and untargeted CD137L
fusion proteins for the immunotherapy of experimental solid
tumors. Clin. Cancer Res. 13, 2758-2767.
69. Nocentini G, Riccardi C. (2005) GITR: A multifaceted
regulator of immunity belonging to the tumor necrosis
factor receptor superfamily. Eur. J. Immunol. 35, 1016-
1022.
70. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H,
et al. (2008) Construction and preclinical characterization of
Fc-mGITRL for the immunotherapy of cancer. Clin. Cancer
Res. 14, 579-588.
71. Mallett SS, Fossum S, Barclay AN. (1990) Characterization
of the MRC OX40 antigen of activated CD4 positive
T lymphocytes—a molecule related to nerve growth factor
receptor. Eur. Mol. Biol. Organ. J. 9, 1063-1068.
72. Weinberg AD, Wegmann KW, Funatake C, Whitham RH.
(1999) Blocking OX-40/OX-40 ligand interaction in vitro and
in vivo leads to decreased T cell function and amelioration of
experimental allergic encephalomyelitis. J. Immunol. 162,
1818-1826.
73. Pippig SD, Pena-Rossi C, Long J, Godfrey WR, Fowell DJ,
Reiner SL, et al. (1999) Robust B cell immunity but impaired
T cell proliferation in the absence of CD134 (OX40).
J. Immunol. 163, 6520-6529.
74. Maxwell JR, Weinberg A, Prell RA, Vella AT. (2000) Danger
and OX40 receptor signaling synergize to enhance memory
T cell survival by inhibiting peripheral deletion. J. Immunol.
164, 107-112.
75. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. (2001)
OX40 promotes Bcl-xL and Bcl-2 expression and is essen-
tial for long-term survival of CD4 T cells. Immunity 15,
445-455.
76. Wang HC, Klein JR. (2001) Multiple levels of activation of
murine CD8 þ intraepithelial lymphocytes defined by OX40
(CD134) expression: effects on cell-mediated cytotoxicity,
IFN-gamma, and IL-10 regulation. J. Immunol. 167, 6717-
6723.
77. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS.
(2002) 4-1BB promotes the survival of CD8 þ T lymphocytes
by increasing expression of Bcl-xL and Bfl-1. J. Immunol.
169, 4882-4888.
78. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, et al.
(2004) 4-1BB and OX40 dual costimulation synergistically
stimulate primary specific CD8 T cells for robust effector
function. J. Immunol. 17, 3002-3012.
79. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A.
(2002) Homeostasis and anergy of CD4 þ CD25 þ suppressor
T cells in vivo. Nat. Immunol. 3, 33-41.
80. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S,
et al. (2004) Distinct roles for the OX40-OX40 ligand inter-
action in regulatory and nonregulatory T cells. J. Immunol.
172, 3580-3589.
52. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein
AL. (1999) Pretreatment with a monoclonal antibody/
interleukin 2 fusion protein directed against DNA enhances
the delivery of therapeutic molecules to solid tumors. Clin.
Cancer Res. 5, 51-60.
53. Mizokami MM, Hu P, Khawli LA, Jaili L, Epstein AL. (2003)
Chimeric TNT-3/murine interferon-( fusion protein for the
immunotherapy of solid malignancies. Hybrid. Hybridomics
22, 197-207.
54. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. (2002)
Generation of human interferon gamma and tumor necrosis
alpha chimeric TNT-3 fusion proteins. Hybrid. Hybridomics
21, 421-432.
55. Mackay CR. (2001) Chemokines: immunology's high impact
factors. Nat. Immunol. 2, 95-101.
56. Howard OMZ, Dong HF, Shirakawa AK, Oppenheim JJ.
(2000) LEC induces chemotaxis and adhesion by interacting
with CCR1 and CCR8. Blood 96, 840-845.
57. Thelen M. (2001) Dancing to the tune of chemokines. Nat.
Immunol. 2, 129-134.
58. Hombach A, Abken H. (2007) Costimulation tunes tumor-
specific activation of redirected T cells in adoptive immuno-
therapy. Cancer Immunol. Immunother. 56, 731-737.
59. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ.
(1994) Comparative analysis of B7-1 and B7-2 co-stimula-
tory ligands: expression and function. J. Exp. Med. 180,
631-640.
60. Futagawa T, Akiba HK, Kodama T, Takeda K, Hosoda Y,
Yagita H, et al. (2002) Expression and function of 4-1BB and
4-1BB ligand on murine dendritic cells. Int. Immunol. 14,
275-286.
61. Vinay DS, Kwon BS. (1998) Role of 4-1BB in immune
responses. Semin. Immunol. 10, 481-489.
62. Gramaglia I, Cooper D, Miner K, Kwon BS, Croft M. (2000)
Co-stimulation of antigen-specific CD4 T cells by 4-1BB
ligand. Eur. J. Immunol. 30, 392-402.
63. DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade
WF, Kwon BS, et al. (1995) Role of 4-1BB ligand
in costimulation of T lymphocyte growth and its upregu-
lation on M12 B lymphomas by cAMP. J. Exp. Med. 181,
985-992.
64. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA,
Hellstrom KE, et al. (1997) Monoclonal antibodies against
the 4-1BB T-cell activation molecule eradicate established
tumors. Nat. Med. 3, 682-685.
65. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. (2001)
Characterization of a phage display-derived human monoclo-
nal antibody (NHS76) counterpart to chimeric TNT-1
directed against necrotic regions of solid tumors. Hybrid.
Hybridomics 20, 305-312.
66. Zheng G, Wang B, Chen A. (2004) The 4-1BB costimulation
augments the proliferation of CD4 þ CD25 þ regulatory
T cells. J. Immunol. 173, 2428-2434.
67. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S,
Vinay DS, et al. (2004) 4-1BB-dependent
inhibition of
Search WWH ::




Custom Search